media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

New breast cancer drug successfully completed Phase 3 trials.

Recently, Celcuity announced that its self-developed pan-PI3K/mTOR inhibitor gedatolisib achieved a clinically meaningful improvement in progression-free survival (PFS) in the Phase 3 clinical trial codenamed Viktoria-1 for advanced breast cancer. This Viktoria-1 clinical trial focused on patients with PIK3CA wild-type advanced breast cancer and employed a highly compelling head-to-head controlled design. The experimental group received triple therapy consisting of gedatolisib, AstraZeneca’s fulvestrant (Faslodex), and Pfizer’s palbociclib (Ibrance), while the control group received the current clinical standard of care—Novartis’ Piqray in combination with fulvestrant. had a statistically and clinically significant improvement in progression-free survival (PFS) . Furthermore, the dual therapy regimen of gedatolisib and fulvestrant also performed well in the key secondary endpoint compared to Piqray plus fulvestrant, validating its therapeutic advantage in this patient population. The release of this significant data quickly generated a positive response in the capital market. Following the announcement, Celcuity’s stock price surged nearly 40% in ...
- Source: drugdu
- 64
- May 8, 2026
This tech giant is spending a whopping 2 billion yuan to accelerate its “AI transformation.”

Recently, Sanofi officially announced that it will invest US$294 million (approximately RMB 2 billion) to expand its global AI Center of Excellence in Toronto. According to the official announcement, this expansion also received a matching grant of up to $5 million from the Ontario Investment Fund . The project is expected to create 50 new high-end professional positions in artificial intelligence, machine learning, and data science by 2028. Prior to this, the center already had more than 150 positions, covering multiple professional fields such as cloud computing, data engineering, software development, bioinformatics, and pharmaceutical data science . The newly recruited talent will be responsible for designing and implementing various AI tools within Sanofi, applying them comprehensively to all aspects of the business, including drug development, manufacturing, and commercial operations. Sanofi’s Chief Digital Officer, Emmanuel Frenehard, publicly stated that artificial intelligence has been deeply integrated into the entire process of research, ...
- Source: drugdu
- 67
- May 8, 2026
Yuandong Bio takes the lead! China’s first acetaminophen-oxycodone extended-release tablets approved

Recently, according to the NMPA website, Chengdu Yuandong Biopharmaceutical Co., Ltd.’s improved new drug, acetaminophen oxycodone extended-release tablets , submitted under the Class 2.2 chemical drug category , has been approved for marketing, making it the first company in China to obtain approval for this dosage form. Acetaminophen/oxycodone extended-release tablets are a potent, centrally acting analgesic composed of the opioid analgesic oxycodone and the nonsteroidal anti-inflammatory drug acetaminophen. The two work synergistically to ensure analgesic efficacy while optimizing medication safety. Compared to domestically marketed acetaminophen/oxycodone immediate-release tablets, its core innovation lies in its dual-layer tablet design —one immediate-release layer and one extended-release layer —achieving long-lasting and stable analgesia, effectively reducing dosing frequency, and significantly improving patient adherence .According to the “China Pain Medicine Development Report,” there are over 300 million chronic pain patients in China, and this number continues to grow by 10-20 million annually, indicating a huge and rigid ...
- Source: drugdu
- 52
- May 8, 2026
Amgen’s innovative drug Evodia® (romoxozimab injection) has been approved in China, helping osteoporosis patients improve their bone health.

Amgen China announced that Evonik® (romoxozimab injection) has been approved by the National Medical Products Administration of China for the treatment of osteoporosis in postmenopausal women at high risk of fracture. As the world’s first and only dual-action biologic that simultaneously promotes bone formation and inhibits bone resorption, the approval of Evonik® provides a new treatment option for osteoporosis patients in China, especially those at very high fracture risk. Studies show that the risk of refracture is highest within 1-2 years after a fracture, and women with a history of fracture have an 86% increased risk of refracture. One in five postmenopausal women with vertebral fractures will experience a new fracture within one year, and 45% of women with hip fractures have reported fragility fractures . The approval of Evonik® is based on the results of several pivotal clinical studies, including the pivotal Phase III clinical trials FRAME and ARCH. ...
- Source: drugdu
- 62
- May 8, 2026
Crizotinol Ointment Approved for Market Launch; Jiudian Topical Products Expands to New Indications

Recently, Jiudian Pharmaceutical’s Crizotinol Ointment officially received registration approval from the National Medical Products Administration, which is considered equivalent to passing the generic drug consistency evaluation. This product is a Class B drug covered by the National Medical Insurance Program and is suitable for the topical treatment of mild to moderate atopic dermatitis in children aged 3 months and older and adults. This approval marks a new breakthrough for Jiudian Pharmaceutical in the field of topical medications, further expanding the therapeutic indications of its topical product portfolio from the anti-inflammatory and analgesic field to the field of skin immune inflammation regulation. Atopic dermatitis is a chronic, relapsing, inflammatory skin disease, and its prevalence among children in my country is showing an increasing trend year by year. For a long time, topical treatment for mild to moderate atopic dermatitis has mainly relied on corticosteroids and calcineurin inhibitors. However, long-term use of ...
- Source: drugdu
- 57
- May 8, 2026
Shanghai Pharmaceuticals’ Rivaroxaban Tablets Receive Thai Drug Registration Certificate

Recently, rivaroxaban tablets produced by Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, received a drug registration certificate issued by the Thai Food and Drug Administration, and the drug has been approved for marketing. Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; to treat and prevent deep vein thrombosis (DVT); to treat pulmonary embolism (PE); and to prevent venous thromboembolism (VTE) in patients with acute illness. Rivaroxaban tablets were originally developed jointly by Bayer and Janssen and were launched in the United States in 2011. In May 2025, Changzhou Pharmaceutical Factory’s rivaroxaban tablets obtained approval from the U.S. Food and Drug Administration. In October 2025, it obtained a drug registration certificate in Malaysia, and in February 2026, it obtained a drug registration certificate in Singapore. According to IQVIA database, the total sales of rivaroxaban tablets in ...
- Source: drugdu
- 49
- May 8, 2026
【EXPERT Q&A】How to apply for a drug business license? What conditions are needed?

Drugdu.com expert’s response: The process and requirements for obtaining a Pharmaceutical Trading License are as follows: I. Application Process 1. Preparation of Application Materials Pharmaceutical Trading License Application Form: Fill in the enterprise’s basic information and application details truthfully. Copy of the Enterprise’s Business License or Name Pre-approval Notice. Personnel Qualification Certificates: Identity certificates, academic certificates, and professional title certificates of the legal representative, enterprise leader, and quality leader. The quality leader must provide a licensed pharmacist registration certificate (for retail enterprises, the quality leader must be a licensed pharmacist). Qualification certificates for personnel engaged in drug inspection, maintenance, and other positions. Site Proof Materials: Property ownership certificates or lease agreements for the business premises and warehouse. Floor plans of the business premises and warehouse, indicating functional areas such as the pending inspection area, qualified area, and unqualified area, in compliance with the Good Supply Practice for Pharmaceutical Products (GSP). ...
- Source: drugdu
- 67
- May 8, 2026
PMEC China 2026

Organiser：Informa Markets Time：June 16 – June 18, 2026 Address：No. 2345 Longyang Road, Pudong New Area, Shanghai Exhibition hall：Shanghai New International Expo Center Product range: Pharmaceutical machinery, packaging equipment, intelligent manufacturing, pharmaceutical packaging materials, drug delivery devices and accessories, laboratory instruments and equipment, clean equipment and engineering, environmental protection and energy-saving equipment, life science instruments, bioengineering, pharmaceutical logistics equipment and services, equipment accessories About PMEC China： The World Pharmaceutical Machinery, Packaging Equipment and Materials China Expo (PMEC China) serves as a vital platform for product trade and information exchange in the global pharmaceutical industry. PMEC China has consistently been committed to showcasing the high-quality products and exceptional research and development capabilities of Chinese equipment manufacturing companies to the world. Meanwhile, numerous overseas buyers also regard PMEC as an important window for gaining insights into the Chinese market.
- Source: drugdu
- 77
- May 7, 2026
【EXPERT Q&A】What is the process for the production filing of Class I medical devices?

Drugdu.com expert’s response: The process for filing the production of Class I medical devices is as follows: 1. Corporate Qualification Preparation Legal Business License: The enterprise must possess a valid business license, with its business scope covering the production of medical devices. Production Conditions: Ensure that the enterprise has the necessary production conditions, including the configuration of hardware facilities such as factory premises, equipment, and personnel. 2. Product Classification Confirmation Class I Confirmation: Confirm that the product falls under the category of Class I medical devices by referring to the “Medical Device Classification Catalog” or consulting regulatory authorities for confirmation. Re-confirmation upon Changes: If there are changes in the product’s function or intended use, re-confirm its classification to avoid misclassification. 3. Filing Document Preparation Core Documents: Class I Medical Device Production Filing Form Product Technical Requirements Document: Clearly specifying performance indicators and testing methods. Production Quality Management Documents: Demonstrating the ...
- Source: drugdu
- 69
- May 6, 2026
IRAN HEALTH

Organiser：SANAT SALAMAT Newsad CO. Time：June 8 – June 11, 2026 Address：Tehran International Permanent Fairground, Chamran Expressway, Vali-e Asr Ave., Tehran, Iran Exhibition hall：Tehran International Exhibition Center Product range: Hospital equipment and medical devices, surgical instruments and medical-related books, X-ray, CT, MRI, nuclear medicine, imaging technology, pharmaceutical and herbal products, home medical equipment, physiotherapy, pharmaceutical raw materials, anesthesiology, respiratory instruments and equipment, pharmaceutical and packaging equipment, surgical techniques and equipment, healthcare products, sterilization and disinfection equipment, clinical chemistry automation devices, emergency medical equipment and pharmaceuticals, biotechnology laboratory equipment, surgical instruments and endoscopic equipment, blood bank equipment and refrigeration equipment, general and specialized diagnostics, dental care and treatment equipment, orthopedic technology and rehabilitation devices, oral care, consumables, and equipment (disinfection and technology) About IRAN HEALTH： The Iran Health Exhibition & Iran Dental Exhibition (IRAN HEALTH) is the most renowned and largest medical and pharmaceutical themed exhibition in Iran. Each year, ...
- Source: drugdu
- 81
- May 5, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.